Significant induction of apoptosis in renal cell carcinoma cells transfected with cationic multilamellar liposomes containing the human interferon-β gene through activation of the intracellular type 1 interferon signal pathway

International Journal of Oncology

Volumn 40, Issue 5, 2012, Pages 1441-1446

  Takaha, Natsuki ^a   Nakanishi, Hiroyuki ^a   Kimura, Yasunori ^a   Hongo, Fumiya ^a   Kamoi, Kazumi ^a   Kawauchi, Akihiro ^a   Mizuno, Masaaki ^b   Yoshida, Jun ^c   Wakabayashi, Toshihiko ^d   Miki, Tsuneharu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

^c CHUBU ROSAI HOSPITAL   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Gene therapy; IAB 1; IFN ; Renal cell carcinoma

Indexed keywords

BETA INTERFERON; BETA INTERFERON RECEPTOR; COMPLEMENTARY DNA; INTERFERON; NEUTRALIZING ANTIBODY;

APOPTOSIS; ARTICLE; CELLULAR DISTRIBUTION; COLORIMETRY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENE INDUCTION; GENE LOCATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; KIDNEY CARCINOMA; LIPOSOMAL GENE DELIVERY SYSTEM; NICK END LABELING; ONCOGENE C MYC; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; COLORIMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENES, REPORTER; HUMANS; IN SITU NICK-END LABELING; INTERFERON REGULATORY FACTORS; INTERFERON-BETA; KIDNEY NEOPLASMS; LIPOSOMES; MICROSCOPY, CONFOCAL; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, INTERFERON; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84860312346     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1377     Document Type: Article

References (26)

1. Rinehart JJ, Young D, Laforge J, Colborn D and Neidhart JA: Phase I/II trial of interferon-beta-serine in patients with renal cell carcinoma: immunological and biological effects. Cancer Res 47: 2481-2485, 1987. (Pubitemid 17099217)
2. Motzer RJ, Bacik J, Murphy BA, Russo P and Mazumdar M: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20: 289-296, 2002. (Pubitemid 34032623)
3. Jonasch E and Haluska FG: Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6: 34-55, 2001. (Pubitemid 32155814)
4. Vuky J and Motzer RJ: Cytokine therapy in renal cell cancer. Urol Oncol 5: 249-257, 2000.
5. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134, 2007. (Pubitemid 46089673)
6. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281, 2007. (Pubitemid 46849157)
7. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456, 2008.
8. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124, 2007. (Pubitemid 46089672)
9. Nakanishi H, Mizutani Y, Kawauchi A, et al: Significant antitumoral activity of cationic multilamellar liposomes containing human IFN-beta gene against human renal cell carcinoma. Clin Cancer Res 9: 1129-1135, 2003. (Pubitemid 36323722)
10. Hoehn W and Schroeder FH: Renal cell carcinoma: two new cell lines and a serially transplantable nude mouse tumor (NC 65). Preliminary report. Invest Urol 16: 106-112, 1978. (Pubitemid 9157407)
11. Natsume A, Tsujimura K, Mizuno M, Takahashi T and Yoshida J: IFN-beta gene therapy induces systemic antitumor immunity against malignant glioma. J Neurooncol 47: 117-124, 2000. (Pubitemid 30665322)
12. Yagi K, Noda H, Kurono M and Ohishi N: Efficient gene transfer with less cytotoxicity by means of cationic multilamellar liposomes. Biochem Biophys Res Commun 196: 1042-1048, 1993. (Pubitemid 23347553)
13. Yoshida J, Mizuno M and Yagi K: Efficient transfection of human interferon-beta gene to human glioma cells by means of cationic multilamellar liposomes coupled with a monoclonal antibody [corrected]. J Neurooncol 19: 269-274, 1994. (Pubitemid 24296635)
14. Mizuno M, Yoshida J, Sugita K, et al: Growth inhibition of glioma cells transfected with the human beta-interferon gene by liposomes coupled with a monoclonal antibody. Cancer Res 50: 7826-7829, 1990.
15. Matsuoka M, Wispriyono B and Igisu H: Increased cytotoxicity of cadmium in fibroblasts lacking c-fos. Biochem Pharmacol 59: 1573-1576, 2000. (Pubitemid 30229890)
16. Mizutani Y, Nakanishi H, Li YN, Sato N, Kawauchi A and Miki T: Enhanced sensitivity of bladder cancer cells to cisplatin mediated cytotoxicity and apoptosis in vitro and in vivo by the selective cyclooxygenase-2 inhibitor JTE-522. J Urol 172: 1474-1479, 2004. (Pubitemid 39249752)
17. Askew DS, Ashmun RA, Simmons BC and Cleveland JL: Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6: 1915-1922, 1991. (Pubitemid 21924028)
18. Couillard M, Guillaume R, Tanji N, D'Agati V and Trudel M: c-myc-induced apoptosis in polycystic kidney disease is independent of FasL/Fas interaction. Cancer Res 62: 2210-2214, 2002. (Pubitemid 34411691)
19. Pelengaris S, Khan M and Evan GI: Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109: 321-334, 2002. (Pubitemid 34606875)
20. Prendergast GC: Mechanisms of apoptosis by c-Myc. Oncogene 18: 2967-2987, 1999.
21. Hyer ML, Voelkel-Johnson C, Rubinchik S, Dong J and Norris JS: Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. Mol Ther 2: 348-358, 2000.
22. Zhang X, Yang Z, Dong L, Papageorgiou A, McConkey DJ and Benedict WF: Adenoviral-mediated interferon alpha overcomes resistance to the interferon protein in various cancer types and has marked bystander effects. Cancer Gene Ther 14: 241-250, 2007.
23. Semova N, Kapanadze B, Corcoran M, Kutsenko A, Baranova A and Semov A: Molecular cloning, structural analysis, and expression of a human IRLB, MYC promoter-binding protein: new DENN domain-containing protein family emerges small star, filled. Genomics 82: 343-354, 2003. (Pubitemid 36952305)
24. Chatterjee D and Savarese TM: Posttranscriptional regulation of c-myc proto-oncogene expression and growth inhibition by recombinant human interferon-beta ser17 in a human colon carcinoma cell line. Cancer Chemother Pharmacol 30: 12-20, 1992.
25. Dani C, Mechti N, Piechaczyk M, Lebleu B, Jeanteur P and Blanchard JM: Increased rate of degradation of c-myc mRNA in interferon-treated Daudi cells. Proc Natl Acad Sci USA 82: 4896-4899, 1985. (Pubitemid 15249912)
26. Sarkar D, Park ES and Fisher PB: Defining the mechanism by which IFN-beta dowregulates c-myc expression in human melanoma cells: pivotal role for human polynucleotide phosphorylase (hPNPaseold-35). Cell Death Differ 13: 1541-1553, 2006. (Pubitemid 44210357)